Phase I Study of Mosperafenib, a Novel Paradox Breaker B-Raf Proto-Oncogene Serine/Threonine Kinase (BRAF) Inhibitor, in Patients With BRAF V600–Mutant Solid Tumors

医学 皮疹 黄斑丘疹 不利影响 药代动力学 结直肠癌 癌症 内科学 肿瘤科 药理学 最大耐受剂量 激酶 实体瘤疗效评价标准 胃肠病学 临床研究阶段 实体瘤 突变 化疗 存活率 癌症研究 胃肠道 毒性
作者
María Vieito,Elisa Fontana,Catherine HyeWon Han,Eduardo Castañón,David James Pinato,Oliver Edgar Bechter,Rikke Løvendahl Eefsen,Irene Moreno,Hans Prenen,Reinhard Dummer,Ruth Plummer,Gabriel Schnetzler,Martin Kornacker,Piergiorgio Pettazzoni,Florian Renner,M. About,Martha L. Serrano‐Serrano,Christina Godfried Sie,K. Abiraj,Andreas Roller
出处
期刊:Journal of Clinical Oncology [Lippincott Williams & Wilkins]
卷期号:44 (14): 1337-1348 被引量:6
标识
DOI:10.1200/jco-25-02444
摘要

PURPOSE: V600 mutations are tumor-agnostic oncogenic drivers whose targeted inhibition is challenged by therapeutic resistance. Mosperafenib is a novel paradox breaker and brain-penetrant BRAF inhibitor (BRAFi), tested in this study for safety, maximum tolerated dose (MTD), pharmacokinetics (PK), and preliminary clinical activity. PATIENTS AND METHODS: V600 mutation (ISRCTN13713551). The modified continuous reassessment method guided dose escalation of mosperafenib, which was given orally up to 3,600 mg once daily in 28-day cycles. The primary objective was to estimate the MTD and/or recommended phase II dose(s). RESULTS: Eighty patients (60% BRAFi-exposed)-63 with colorectal cancer (CRC), 13 with melanoma, and 4 with other solid tumors-received ≥1 dose of mosperafenib as a single agent for a median of 3.7 months (range, 0.2-28.6). Two dose-limiting grade 3 toxicities of rash and rash maculopapular were reported. MTD was not reached. Grade 3 to 4 treatment-related adverse events (TRAEs) occurred in 13 patients (16.3%); no grade 5 TRAEs events were reported. Two patients (2.5%) discontinued study treatment due to TRAEs. There were no reports of palmar-plantar erythrodysesthesia or keratoacanthoma. Linear and time-independent PK was demonstrated across the tested dose range, achieving exposure levels with sustained PK-derived pERK inhibition ≥90%. An exposure-response relationship was observed. Overall response rate was 24.2%, including two complete responses and 14 partial responses. Median progression-free survival was 6.4 months in patients with CRC (200 mg once daily-1200 mg three times a day) and 3.5 months in patients with melanoma (200 mg once daily-800 mg twice a day). CONCLUSION: Mosperafenib demonstrated a favorable safety profile, sustained target inhibition, and early signs of clinically meaningful single-agent activity in BRAFi-naïve and BRAFi-exposed patients.
最长约 10秒,即可获得该文献文件

科研通智能强力驱动
Strongly Powered by AbleSci AI
科研通是完全免费的文献互助平台,具备全网最快的应助速度,最高的求助完成率。 对每一个文献求助,科研通都将尽心尽力,给求助人一个满意的交代。
实时播报
mikiyoo完成签到,获得积分10
刚刚
科研通AI6.2的应助被外向夜阑采纳,获得10
1秒前
1秒前
ZTF完成签到,获得积分10
1秒前
JamesPei的应助被泽ze采纳,获得10
1秒前
ding的应助被飞翔868采纳,获得10
1秒前
WhiteCaramel完成签到 ,获得积分10
1秒前
山复尔尔发布了新的文献求助10
1秒前
喷火娃的应助被wumin26采纳,获得10
2秒前
2秒前
2秒前
Hello_glacier发布了新的文献求助10
2秒前
疯狂的石头完成签到,获得积分10
2秒前
曾经的雅琴完成签到,获得积分10
3秒前
3秒前
彭于晏的应助被xliang采纳,获得10
3秒前
李健的小迷弟的应助被an采纳,获得10
3秒前
科研通AI6.4的应助被小羊采纳,获得10
3秒前
ReynaLi发布了新的文献求助10
3秒前
ccc完成签到,获得积分10
3秒前
Hih发布了新的文献求助10
4秒前
夏艳萍发布了新的文献求助10
5秒前
小北完成签到 ,获得积分10
5秒前
勤奋的熊猫完成签到,获得积分10
5秒前
清秀斓完成签到,获得积分10
5秒前
dpl发布了新的文献求助50
6秒前
风中的渊思完成签到,获得积分10
6秒前
6秒前
山复尔尔发布了新的文献求助10
6秒前
7秒前
包子牛奶完成签到,获得积分10
7秒前
7秒前
ruixinwang完成签到,获得积分10
7秒前
乐乐的应助被kk采纳,获得10
7秒前
7秒前
ding的应助被FY采纳,获得10
7秒前
Li完成签到,获得积分20
7秒前
7秒前
黑白完成签到 ,获得积分10
7秒前
酷酷的寄风完成签到,获得积分10
8秒前
高分求助中
(应助此贴封号)【重要!!请各用户(尤其是新用户)详细阅读】【科研通的精品贴汇总】 10000
拉伸高分子熔体中缠结行为的模拟和小角中子散射研究 1700
奈特基础组织学:配套组织病理学(第4版)(Netter's Essential Histology With Correlated Histopathology) 800
John McDowells Bildungstheorie 800
八旗制度の研究 600
plantTFDB 508
高分子基功能界面水蒸发材料与应用研究 500
热门求助领域 (近24小时)
化学 材料科学 医学 生物 纳米技术 计算机科学 工程类 有机化学 化学工程 生物化学 物理 复合材料 内科学 催化作用 光电子学 人工智能 细胞生物学 无机化学 物理化学 数学
热门帖子
关注 科研通微信公众号,转发送积分 8176481
求助须知:如何正确求助?哪些是违规求助? 9567855
关于积分的说明 21795109
捐赠科研通 7771163
什么是DOI,文献DOI怎么找? 3432027
关于科研通互助平台的介绍 2556365
邀请新用户注册赠送积分活动 2477695